We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+22.67%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$931M
AUM Growth
-$79.5M
Cap. Flow
-$212M
Cap. Flow %
-22.74%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$39.8M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$252M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 54.85%
2 Healthcare 45.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVA icon
1
CAVA Group
CAVA
$7.1B
$511M 54.85%
6,507,990
-3,000,000
-32% -$252M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$997M
$420M 45.15%
175,156,062
+20,421,735
+13% +$39.8M

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2026 Portfolio in Review

As of Q2 2026, Artal Group held 2 positions worth $931M, down 7.9% from $1.01B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Artal Group withdrew a net $212M in Q2 2026, reducing 1 holding. Its largest reduction was CAVA Group, cutting an estimated $252M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 55% of assets, down from 76% a quarter earlier, followed by Healthcare.

Against the trend, Artal Group added an estimated $39.8M to Lexicon Pharmaceuticals.

  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2026, an estimated $39.8M increase.
  • Artal Group's biggest Q2 2026 reduction was CAVA Group, cutting an estimated $252M.
  • Artal Group's ten largest holdings make up 100% of its $931M portfolio in Q2 2026.
  • Artal Group opened 0 new positions and closed 0 in Q2 2026.
  • Artal Group's portfolio value fell 7.9% quarter-over-quarter to $931M.

Based on Artal Group's 13F filing for Q2 2026, filed 13 Aug 2026.